CLINICAL RESEARCH

e-ISSN 1643-3750 © Med Sci Monit, 2024; 30: e944294 DOI: 10.12659/MSM.944294

**MEDICAL<br>SCIENCE MONITOR** 

Received: 2024.02.28 Accepted: 2024.05.21 Available online: 2024.06.04 Published: 2024.07.06

# Identification of RESP18 Gene Mutations Linked to Hereditary Non-Syndromic Cleft Lip and Palate in a Southern Chinese Family





e944294-1

made by its manufacturer, is not guaranteed or endorsed by the publisher

Publisher's note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be

# Introduction

Non-syndromic cleft lip with cleft palate (NSCLP) is one of the most common congenital birth defects worldwide, and occurs in approximately 1 in 1000 live births [1-3]. NSCLP can be classified into 5 types – (A) Cleft lip and alveolus, (B) Cleft palate, (C) Incomplete unilateral cleft lip and palate, (D) Complete unilateral cleft lip and palate, and (E) Complete bilateral cleft lip and palate – all of which are caused by mesenchymal tissues disorders in cell migration, growth, differentiation, and apoptosis at 4-10 weeks of human embryonic development [4]. Although it is not a main cause of death, this serious malformation has a lifelong impact on health and causes substantial financial and social burdens to patients and their families, and is challenging to treat [2,3,5,6]. Previous studies have shown that the etiology of NSCLP is heterogeneous and closely related to genetic and environmental factors [1,3,4,7]. However, a singlegene mutation may contribute more significance in a hereditary NSCLP family [8]. There have been few studies on shared related mutant genes in NSCLP families. Thus, identification of susceptible variants plays an important role in prevention, treatment, and prognosis of people with NSCLP.

Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are the most extensively used and effective genomics methods in medical genetics, which can more comprehensively identify single-nucleotide variation (SNV), single-nucleotide polymorphism (SNP), insertion deletion mutation (INDEL), copy number mutation (CNV), and structural variation (SV) in the whole genome of hereditary diseases [9,10]. Whole-genome sequencing sequences all genes, detected exons, introns, and regulatory sequences, and screens the genetic variation in the genome, allowing genotype diversity analysis, genetic evolution analysis, disease pathogenesis, and susceptibility gene screening [2,9,11,12]. WGS is increasingly utilized in the research, screening, and monitoring of various diseases. Turro et al used WGS to identify the associations between genes and diseases and Wong et al discovered an actionable target for highrisk childhood cancer by using WGS [11,12]. Whole-exome sequencing (WES) is a more efficient, complete, specific, and inexpensive sequencing technology for studying the etiology of hereditary diseases [13-16]. Basha et al used whole-exome sequencing (WES) to identify variant genes in NSCLP, and found that the susceptibility genes are not only helpful in revealing the etiology of NSCLP, but also help in diagnosis and treatment of patients with NSCLP [17-19]. Many studies have explored the causes of NSCLP [18,20-22]. However, these observations suggested that different populations have different causal variants due to different genetic backgrounds., Leslie and Marazita reviewed orofacial clefts with the many error genes that contributed to the etiology of birth defects [23]. Few studies have explored genomic loci mutation related to NSCLP among Chinese people [24].

In this study, we performed genomic analysis through sequencing technique and identification of de novo RESP18 rs2385404 and rs2385405 gene polymorphisms associated with NSCLP in a southern Chinese family. Our findings provide important insights into the etiology of NSCLP.

# Material and Methods

#### **Participants**

A 5-member family with hereditary NSCLP was recruited by the Cleft Lip and Palate Treatment Center of Shantou University Medical College. The adults and the parents/guardians of the children provided informed consent for genetic testing. Three plastic surgeons with attending physician qualification were invited for clinical examination and diagnosis. Complete physical examinations were performed to exclude other organ malformations, deformities, and to identify CL/P. Considering that 5 subjects from the 1 hereditary family lived in the same conditions, variables were deemed to be identical. This study has been checked by the second affiliated hospital of Shantou university medical ethics examination department (2020-24).

We obtained clinical information and peripheral blood samples from each recruited family member. Five members participated in the study (**Figure 1**, black dotted rectangle). Three members had complete cleft lip and palate and 2 were normal controls (Normal 1 and Normal 2). The parents were II3 (Cleft 1) and II4 (Cleft 2) and both had unilateral complete cleft lip and palate, while III2 (Cleft 3) was the son with bilateral complete cleft lip and palate. This study was approved by the ethics committees of the Shantou University Medical College.

#### Genomic Analysis

Whole-genome sequencing and whole-exome sequencing were performed by LC-Bio Co., Ltd. (Hangzhou, China, www.lc-bio. com). Genomic DNA was extracted from patients' peripheral blood. We used RNA 6000 Nano LabChip Kits (Agilent, CA, USA) to ensure the genomic DNA samples were of high quality, with OD 260/280 ratio 1.8-2.0. The DNA library constructed from human samples using the High Sensitivity DNA Chip Kit (Agilent, CA, USA) and Agilent SureSelect Human All Exon V6 (Agilent, CA, USA) was sequenced and run with the Illumina HiSeq2500/4000 sequence platform.

For the alignment step, sequenced reads were aligned to the reference genome (UCSC Genome Browser hg19) by Burrows-Wheeler Aligner (BWA, Oxford, UK), and then sorted (Samtools v1.3.1) and repeated markers (Picard v1.141) [25]. In the second post-alignment processing step, a local read realignment is performed to correct potential alignment errors around



Figure 1. Pedigree of the non-syndromic cleft lip with cleft palate (NSCLP) family. II3, II4, and III2: the proband with the phenotype of NSCLP. I1, I2, I3, I4, II1, II2, II5, II6, III1, III3, and III4: members of the pedigree with no NSCLP phenotype. II3, II4, III2, III3, and III4 represent Cleft\_1, Cleft\_2, Cleft\_3, Normal\_1, and Normal\_2, respectively. The black symbols represent an affected member, and the arrow indicates the proband. Five members participated in the study (Figure 1, black dotted rectangle).

indel. Mapping of reads around indel edge usually results in misaligned bases, creating false-positive SNP calls. Local realignment uses these mismatched bases to determine whether sites should be realigned, and applies a computation-intensive algorithm to determine the most consistent position of reads relative indel and to remove misalignment artifacts. More details are available from LC-Bio Co., Ltd. (Hangzhou, China, www.lc-bio.com).

# Variant Calling

Each cardinality read has an associated quality score corresponding to the probability of sequencing error. Due to systematic biases, the reported quality scores are known to be inaccurate, so it must be recalibrated prior to genotyping. After recalibration, the recalibrated quality score in the output BAM will be closer to the probability of a sequencing error [25].

Variant calls can be generated with the Genome Analysis Toolkit (GATK, https://www.broadinstitute.org/gatk/guide/best-practices), which examine the evidence for variation from reference via Bayesian inference. The Gaussian mixture model is suitable for assigning an accurate confidence score to each putative mutation call and for evaluating new potential variants.

## Variant Annotation

Biological functional annotation is a crucial step in finding the links between genetic variation and disease. SnpEff is utilized to add biological information to a set of variants.

ANNOVAR software tool and in-house codes were used to annotate all of the mutations with Clinical Variation Data Base (https://www.ncbi.nlm.nih.gov/clinvar/). For further screening, the 1000 Genomes Project (http://www.1000genomes. org/), the Exome Aggregation Consortium (ExAC) Browser, SIFT (http://sift.jcvi.org), and PolyPhen-2 (http://genetics.bwh. harvard.edu/pph2/) were used to predict mutation function.

## Sanger Sequencing

Sanger sequencing was performed by SJ-Bio Co., Ltd. (Guangzhou, China, www.saikabio.com). Premier 3.0 was used for primer design; the primer sequences are listed in **Supplementary Table 1**. Sanger sequencing products were separated using an ABI 3730 genetic analyzer, and the data were analyzed using Chromas V1.0.0.1.

# Results

# Clinical Characteristic

The subjects were a southern Han Chinese family with familial non-syndromic cleft lip and palate (**Figure 1**). In this family, II3, II4, and III2 were the probands with NSCLP phenotype. I1, I2, I3, I4, II1, II2, II5, II6, III1, III3, and III4 were members of the pedigree without NSCLP phenotype. In this study, 5 members were enrolled. Three had complete cleft lip and palate and 2 were normal controls. All of them were diagnosed and treated at the Cleft Lip and Palate Treatment Center of Second Affiliated



**Figure 2.** Clinical manifestation of the NSCLP pedigree. (**A**) (II3) and (**B**) (II4) were parents with unilateral complete cleft lip and palate after surgery, (**C**) (III2) was the son with bilateral complete cleft lip and palate before surgery. (**D**) shows the clinical features of the proband 1 year after surgery.

Hospital of Shantou University Medical College. Among these patients, II3 (**Figure 2A**) and II4 (**Figure 2B**) were the parents, with unilateral complete cleft lip and palate after surgery, III2 (**Figure 2C**) was the son, with bilateral complete cleft lip and palate before surgery. **Figure 2D** shows the clinical feature of the proband 1 year after surgery. According to these clinical features, whole-genomic sequencing and whole-exome sequencing was used to detect possible genetic lesions to explain these abnormal symptoms.

#### Genomic Sequencing

Whole-genome sequencing (WGS) and whole-exome sequencing (WES) were employed to evaluate 5 people of the 2 generations in the NSCLP family. WGS quality summary for the raw data is summarized in **Table 1 and Figure 3**. The Phred quality score (Q), which is the logarithm of the base error rate P, describes how reliable each sequencing base is. For example, if a base is 99% correct, the mass value is 20 (Q20), and if a base is 99.9% correct, the mass value is 30 (Q30). In the WGS result, the total effective data ranged from 92.56 billion

base pairs (Gb) with 31.98 depth (x) to 108.5 billion base pairs (Gb) with 37.49 depth (x). On average, the ratio of valid data was 99.9%. The average ratio of Q20%, Q30%, and GC% were 97.64%, 93.70%, and 41.31%, respectively. WES quality for the raw data is summarized in **Table 2**. The average total effective data were 12.60 billion base pairs (Gb) with 217.24 depth (x). On average, the ratio of valid data was 98.2%. The average ratio of Q20%, Q30%, and GC% were 98.35%, 95.47%, and 53.44%, respectively. When measured at a minimum depth of 2×, 97.61% of the target region was covered. Likewise, when measured at 10×, 20×, and 30×, 96.04%, 92.15%, and 85.00% of the intended target was covered, respectively (**Figure 4**). Thus, the depth and coverage should be adequate to reliably detect DNA variants within the majority of the targeted regions.

**Table 1.** WGS quality summary for the raw data.

## Genetic Findings

The 1000 Genomes Project, the Exome Aggregation Consortium (ExAC) Browser, SIFT, and PolyPhen-2 were used to annotate the structure mutation function. As a result, a total of 7624 mutations were screened, including 1754 mutations in the WGS cohort (23.0%) and 123 mutations in the WES cohort (1.6%). The combination analysis of WGS, WES, and Clinical Variation Data Base showed that a total of 9 variant positions (*RESP18, LSR, SPATS2L, ZNF277, IHH, C2orf69, KIR3DL1, MUC3A, and PRKAG3*) was overlap between the 3 study cohorts (**Figure 5**). Among these variant positions, 2 mutation sites (rs2385404 and rs2385405) related to cleft lip and palate in the *RESP18* gene were found, and the homozygous mutant was companied with more severe symptoms in NSCLP patients, which were



WGS - whole-genomic sequencing. II3, II4, III2, III3 and III4 represent Cleft\_1, Cleft\_2, Cleft\_3, Normal\_1 and Normal\_2, respectively.



e944294-5

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]



**Figure 3.** Depth and coverage of whole-genomic sequencing (WGS). (**A**) The sequence depth and cumulative sequence depth of WGS. (**B**) The coverage and coverage of depth of WGS. II3, II4, III2, III3, and III4 represent Cleft\_1, Cleft\_2, Cleft\_3, Normal\_1, and Normal\_2, respectively.





WES – whole-exome sequencing. II3, II4, III2, III3, and III4 represent Cleft\_1, Cleft\_2, Cleft\_3, Normal\_1, and Normal\_2, respectively.

non-synonymous single-nucleotide variations (SNVs) and resulted in functional changes. Eight mutations were excluded because no similar missense variants were found; for example, some are synonymous variants or are less related to lateral or bilateral compared with regulated endocrine-specific protein 18 (RESP18). To verify the DNA sequence variation detected by WES, the criterion standard method Sanger sequencing was employed.

#### Sanger Sequencing

Using Sanger sequencing, 2 variant positions (rs2385404 and rs2385405) of the *RESP18* gene (NM\_001007089.4) were detected in all 5 family members. Sanger sequencing validation showed that both rs2385404 and rs2385405 had mutations consistent with the WGS and WES results (**Figure 6**). Sanger sequencing results indicated that the mutation of *RESP18* (rs2385404, c.90G>T, p. Glu30Asp) resulted in the transformation of Glu into Asp in the amino acid sequence of *RESP18* protein. Sanger sequencing results indicated that the *RESP18* variant (rs2385405, c.157G>A, p. Glu53Lys) resulted in the transformation of Glu into Lys in the amino acid sequence of the *RESP18* protein. Both rs2385404 and rs2385405 were missense variants. Therefore, this result confirmed that the *RESP18* gene variant was the causal variation in this pedigree.



This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

e944294-7

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]



**Figure 4.** Depth and coverage of whole-exome sequencing (WES). (**A**) The sequence depth and cumulative sequence depth of WES. (**B**) The depth of coverage in WES. (**C**) The sequence coverage when depth at 2×, 10×, 20×, and 30×. II3, II4, III2, III3 and III4 represent Cleft\_1, Cleft\_2, Cleft\_3, Normal\_1, and Normal\_2, respectively.



## **Discussion**

Non-syndromic cleft lip with cleft palate (NSCLP) is one of the most common congenital malformations in China, almost 20% of which are familial cases [21,26]. NSCLP is associated with various factors, and the pathogenesis of NSCLP is not completely clear. It is believed that susceptibility genes are closely related to NSCLP caused by abnormal palatal morphogenesis and tissue fusion during embryonic development [24,27-29]. A variety of approaches have been used to identify key genes contributing to NSCLP through linkage analysis, genomic rearrangements, candidate genes, and

**Figure 5.** Venn diagram of variant position between WGS cohort (filled in green), WES cohort (filled in yellow) and ClinVar cohort. A total of 7624 mutations were screened, including 1754 mutations in the WGS cohort (23.0%) and 123 mutations in the WES cohort (1.6%). Nine variant positions overlapped between the 3 study cohorts (*RESP18, LSR, SPATS2L, ZNF277, IHH, C2orf69, KIR3DL1, MUC3A, PRKAG3*), and 2 of them were rs2385405 and rs2385404 in *RESP18* gene. WGS, whole-gonome sequencing. WES – whole-exome sequencing. ChinVar cohort – Clinical Variation Data Base. NCBI showed that these 2 mutation sites could affect the synthesis and function of *RESP18* protein. NCBI, National Center for Biotechnology Information.

> genome-wide association studies (GWAS) [23]. Researchers found several variants on *SATB2* and *IRF6* genes, which are closely related to the causes of NSCLP [17,30,31]. Yu et al performed GWAS on NSCLP and identified 41 SNPs of achieve genome-wide significance within 26 loci on 14 genes (*RAD54B, TMEM19, KRT18, WNT9B, GSC/DICER1, PTCH1, RPS26, OFCC1/TFAP2A, TAF1B, FGF10, MSX1, LINC00640, FGFR1, and SPRY1*) [2]. Awotoye et al conducted whole-genome sequencing (WGS) analyses in Africa to identify 162 high-confidence protein-altering de novo mutations (DNMs) that were predicted to be pathogenic [22]. The study of Hoebel et al processed whole-exome sequencing (WES) in individuals from independent families and suggested rare variants of 5 candidate genes (*ACACB, PTPRS, MIB1, GRHL3, CREBBP*), which might contribute to NSCLP risk [13]. Polymerase chain reaction and Sanger sequencing were used to genotype rs7078160 in *Vax1*, shown by



**Figure 6.** Sanger sequencing confirmed the variants (rs2385404 and rs2385405) in the *RESP18* gene sequence (GRCh38.p14 chr2). (**A**) Sanger sequencing showed that the mutation of *RESP18* (rs2385404, c.90G>T, p. Glu30Asp) resulted in the transformation of Glu into Asp in the amino acid sequence of *RESP18* protein. (**B**) Sanger sequencing results indicated that the *RESP18* variant (rs2385405, c.157G>A, p. Glu53Lys) resulted in the transformation of Glu into Lys in the amino acid sequence of the *RESP18* protein. Glu – glutamic acid, Asp – aspartic acid, Lys – lysine.

GWAS to be closely related to NSCLP in European populations, and compared mutation through case–control and family-based associations [32]. Therefore, NSCLP may be associated with the mutation of candidate genes.

In the present study, we used whole-genome sequencing (WGS) and whole-exome sequencing (WES) to identify susceptible variants in a south-eastern Han Chinese NSCLP family. In this family, the parents (II3 and II4) had unilateral complete cleft lip and palate, while III2 had bilateral complete cleft lip and palate. Genomic analysis showed that there are 2 mutations in *RESP18* gene in the NSCLP family. Coincidentally, patient II3 and II4 had heterozygous mutations and III2 had homozygous mutations. Our results suggest that the NSCLP phenotypic differences and severity were associated with *RESP18* gene mutations. The same result was obtained from further Sanger sequencing. As a result, we consider *RESP18* is an important gene in NSCLP development and is related to the severity of cleft palate.

Regulated endocrine-specific protein 18(*RESP18*) is an 18-kilodalton protein which mainly exists in the endoplasmic reticulum (ER) [33,34]. As an important glucocorticoid-reactive protein in the adrenocorticotropic hormone secretion pathway, *RESP18* is regulated by physiological and pharmacological stimuli such as dopamine, glucocorticoids, and insulin [35-37]. Furthermore, *RESP18* participates in regulation of the limbic system and autonomic function, regulates the growth of cytoskeleton and neurite, and then affects organ development through post-transcriptional O-glycosylation [38-41]. Therefore, *RESP18* may be an important link in development of the maxillofacial region, and its abnormal expression has a great impact on the occurrence of cleft lip and palate [42-44].

In conclusion, the incidence and condition of NSCLP are related to *RESP18* gene mutation. We speculate that the *RESP18* gene plays an important role in the pathogenesis of cleft lip and palate, and this gene may be relevant to etiology prediction for NSCLP families.

e944294-9

A limitation of the present study is that we only investigated 1 NSCLP southern Han Chinese family. We need to expand the sample to verify this results in further study to eliminate sampling errors. In addition, although *RESP18* gene mutation has been found in NSCLP patients, it is still necessary to verify the function and pathogenesis of the gene in future studies.

results showed that 2 mutations (rs2385404 and rs2385405) of the *RESP18* gene were found in patients in this NSCLP family. Sanger sequencing validation were consistent with the former results. Moreover, we found that *RESP18* gene mutation resulting in amino acid and function changes in proteins. As a result, we speculate the *RESP18* gene plays an important role in the etiology and pathogenesis of cleft lip and palate.

# Conclusions

WGS, WES, and Clinical Variation Data Base (ClinVar) were used to detect the gene variant in a southern Han Chinese family with non-syndromic cleft lip with cleft palate. The combined genomic

## Declaration of Figures' Authenticity

All figures submitted have been created by the authors, who confirm that the images are original with no duplication and have not been previously published in whole or in part.

# Supplementary Table

**Supplementary Table 1.** Primer sequence of RESP18 mutations. RESP18, regulated endocrine-specific protein 18.



# References:

- 1. Dixon MJ, Marazita ML, Beaty TH, Murray JC. Cleft lip and palate: Understanding genetic and environmental influences. Nat Rev Genet. 2011;12(3):167-78
- 2. Yu Y, Zuo X, He M, et al. Genome-wide analyses of non-syndromic cleft lip with palate identify 14 novel loci and genetic heterogeneity. Nat Commun. 2017;8:14364
- 3. Zhao H, Zhang M, Zhong W, et al. A novel IRF6 mutation causing non-syndromic cleft lip with or without cleft palate in a pedigree. Mutagenesis. 2018;33(3):195-202
- 4. Mossey PA, Little J, Munger RG, et al. Cleft lip and palate. Lancet (London, England). 2009;374(9703):1773-85
- 5. Sun Y, Huang Y, Yin A, et al. Genome-wide association study identifies a new susceptibility locus for cleft lip with or without a cleft palate. Nat Commun. 2015;6:6414
- 6. Parameters for evaluation and treatment of patients with cleft lip/palate or other craniofacial differences. Cleft Palate Craniofac J. 2018;55(1):137-56
- 7. Stuppia L, Capogreco M, Marzo G, et al. Genetics of syndromic and nonsyndromic cleft lip and palate. J Craniofac Surg. 2011;22(5):1722-26
- 8. Zhang J, Zhao H, Huang W, et al. A novel FZD6 mutation revealed the cause of cleft lip and/or palate in a Chinese family. Genes Dis. 2020;7(3):440-47
- 9. Hong X, Qiao S, Li F, et al. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: Leading to a new classification system. Gut. 2020;69(5):877-87
- 10. Staaf J, Glodzik D, Bosch A, et al. Whole-genome sequencing of triplenegative breast cancers in a population-based clinical study. Nat Med. 2019;25(10):1526-33
- 11. Turro E, Astle WJ, Megy K, et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature. 2020;583(7814):96-102
- 12. Wong M, Mayoh C, Lau LMS, et al. Whole-genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26(11):1742-53
- 13. Hoebel AK, Drichel D, van de Vorst M, et al. Candidate genes for nonsyndromic cleft palate detected by exome sequencing. J Dent Res. 2017;96(11):1314-21
- 14. Demeer B, Revencu N, Helaers R, et al. Unmasking familial CPX by WES and identification of novel clinical signs. Am J Med Genet A. 2018;176(12):2661-67
- 15. Dai G, Pu Z, Cheng X, et al. Whole-exome sequencing reveals novel genetic variation for dilated cardiomyopathy in pediatric Chinese patients. Pediatr Cardiol. 2019;40(5):950-57
- 16. Wu W, Zhai G, Xu Z, et al. Whole-exome sequencing identified 4 loci influencing craniofacial morphology in northern Han Chinese. Hum Genet. 2019;138(6):601-11
- 17. Liu YP, Xu L-F, Wang Q, et al. Identification of susceptibility genes in nonsyndromic cleft lip with or without cleft palate using whole-exome sequencing. Med Oral Patol Oral Cir Bucal. 2015;20(6):e763-70
- 18. Basha M, Demeer B, Revencu N, et al. Whole-exome sequencing identifies mutations in 10% of patients with familial non-syndromic cleft lip and/or palate in genes mutated in well-known syndromes. J Med Genet. 2018;55(7):449-58
- 19. Adhikari AN, Gallagher RC, Wang Y, et al. The role of exome sequencing in newborn screening for inborn errors of metabolism. Nat Med. 2020;26(9):1392-97
- 20. Demeer B, Revencu N, Helaers R, et al. Likely pathogenic variants in one third of non-syndromic discontinuous cleft lip and palate patients. Genes (Basel). 2019;10(10):833
- 21. Xu T, Du M, Bu X, et al. Identification of a novel TP63 mutation causing nonsyndromic cleft lip with or without cleft palate. BMC Med Genomics. 2021;14(1):53
- 22. Awotoye W, Mossey PA, Hetmanski JB, et al. Whole-genome sequencing reveals de novo mutations associated with nonsyndromic cleft lip/palate. Sci Rep. 2022;12(1):11743
- 23. Leslie EJ, Marazita ML. Genetics of cleft lip and cleft palate. Am J Med Genet C Semin Med Genet. 2013;163c(4):246-58
- 24. Cheng X, Du F, Long X, Huang J. Genetic inheritance models of non-syndromic cleft lip with or without palate: From monogenic to polygenic. Genes. 2023;14(10):1859
- 25. Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489-94

e944294-10

- 26. Li C, Lan Y, Jiang R. Molecular and cellular mechanisms of palate development. J Dent Res. 2017;96(11):1184-91
- 27. Xing Y, Zhang W, Zhao H, et al. Multiorgan assessment via a 9.4Tesla MRS evaluation of metabolites during the embryonic development of cleft palate induced by dexamethasone. Mol Med Rep. 2019;20(4):3326-36
- 28. Zhang W, Shen Z, Xing Y, et al. MiR-106a-5p modulates apoptosis and metabonomics changes by TGF-beta/Smad signaling pathway in cleft palate. Exp Cell Res. 2020;386(2):111734
- 29. Zhang W, Zhao H, Chen J, et al. A LCMS-based untargeted lipidomics analysis of cleft palate in mouse. Mech Dev. 2020;162:103609
- 30. Zhang W, Tan L, Xing Y, et al. Association between *SATB2* gene polymorphism and cleft palate only risk in eastern Guangdong population and a meta-analysis. Cell Mol Biology (Noisy-le-Grand). 2018;64(14):101-7
- 31. Xing Y, Zhang W, Wan X, et al. Association between an interferon regulatory factor 6 gene polymorphism and nonsyndromic cleft palate risk. Genet Test Mol Biomarkers. 2019;23(9):652-63
- 32. Wang Q, Sun S, Song Q, et al. The risk of nonsyndromic cleft lip with or without cleft palate and Vax1 rs7078160 polymorphisms in southern Han Chinese. Braz J Otorhinolaryngol. 2021;87(6):718-22
- 33. Huang Y, Xu J, Liang M, et al. RESP18 is involved in the cytotoxicity of dopaminergic neurotoxins in MN9D cells. Neurotox Res. 2013;24(2):164-75
- 34. Su J, Wang H, Yang Y, et al. RESP18 deficiency has protective effects in dopaminergic neurons in an MPTP mouse model of Parkinson's disease. Neurochem Int. 2018;118:195-204
- 35. Bloomquist BT, Darlington DN, Mueller GP, et al. Regulated endocrine-specific protein-18: A short-lived novel glucocorticoid-regulated endocrine protein. Endocrinology. 1994;135(6):2714-22
- 36. Darlington DN, Schiller MR, Mains RE, Eipper BA. Expression of RESP18 in peptidergic and catecholaminergic neurons. J Histochem Cytochem. 1997;45(9):1265-77
- 37. Torkko JM, Primo ME, Dirkx R, et al. Stability of proICA512/IA-2 and its targeting to insulin secretory granules require beta4-sheet-mediated dimerization of its ectodomain in the endoplasmic reticulum. Mol Cell Biol. 2015;35(6):914-27
- 38. Liang M, Yang JL, Bian MJ, et al. Requirement of regulated endocrine-specific protein-18 for development and expression of regulated endocrinespecific protein-18 isoform c in mice. Mol Biol Rep. 2011;38(4):2557-62
- 39. Atari E, Perry MC, Jose PA, Kumarasamy S. Regulated endocrine-specific protein-18, an emerging endocrine protein in physiology: A literature review. Endocrinology. 2019;160(9):2093-100
- 40. Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15(6):346-66
- 41. Li X, Gong W, Wang H, et al. O-GlcNAc transferase suppresses inflammation and necroptosis by targeting receptor-interacting serine/threonine-protein kinase 3. Immunity. 2019;50(3):576-90.e6
- 42. Estevez A, Zhu D, Blankenship C, Jiang J. Molecular interrogation to crack the case of O-GlcNAc. Chemistry. 2020;26(53):12086-100
- 43. Lin L, Kightlinger W, Prabhu SK, et al. Sequential glycosylation of proteins with substrate-specific N-glycosyltransferases. ACS Cent Sci. 2020;6(2):144-54
- 44. Schwein PA, Woo CM. The O-GlcNAc modification on kinases. ACS Chem Biol. 2020;15(3):602-17